J. Scott Wolchko
Net Worth

Last updated:

What is J. Scott Wolchko net worth?

The estimated net worth of Mr. J. Scott Wolchko is at least $51,786,449 as of 9 Jan 2024. He owns shares worth $423,148 as insider, has earned $41,174,551 from insider trading and has received compensation worth at least $10,188,750 in Fate Therapeutics, Inc..

What is the salary of J. Scott Wolchko?

Mr. J. Scott Wolchko salary is $926,250 per year as Founder, Chief Executive Officer, Pres & Director in Fate Therapeutics, Inc..

How old is J. Scott Wolchko?

Mr. J. Scott Wolchko is 55 years old, born in 1970.

What stocks does J. Scott Wolchko currently own?

As insider, Mr. J. Scott Wolchko owns shares in one company:

Company Title Shares Price per share Total value
Fate Therapeutics, Inc. (FATE) Founder, Chief Executive Officer, Pres & Director 371,248 $1.14 $423,148

What does Fate Therapeutics, Inc. do?

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE logo
FATE
Fate Therapeutics, Inc.
$1.14

J. Scott Wolchko insider trading

Fate Therapeutics, Inc.

Mr. J. Scott Wolchko has made 51 insider trades between 2014-2024, according to the Form 4 filled with the SEC. Most recently he sold 14,391 units of FATE stock worth $62,889 on 9 Jan 2024.

The largest trade he's ever made was exercising 60,820 units of FATE stock on 8 Jan 2021. As of 9 Jan 2024 he still owns at least 371,248 units of FATE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 14,391 $4.37 $62,889
Sale
Common Stock 45,907 $5.24 $240,553
Sale
Common Stock 2,703 $32.61 $88,145
Option
Stock Option (Right to Buy) 6,246 $2.7 $16,864
Option
Common Stock 6,246 $2.7 $16,864
Sale
Common Stock 620 $33.28 $20,634
Sale
Common Stock 2,923 $31.33 $91,578
Option
Stock Option (Right to Buy) 30,000 $2.7 $81,000
Sale
Common Stock 19,171 $33.07 $633,985
Sale
Common Stock 10,829 $32.54 $352,376
Option
Common Stock 30,000 $2.7 $81,000
Sale
Common Stock 838 $35.15 $29,456
Sale
Common Stock 9,162 $34.54 $316,455
Option
Stock Option (Right to Buy) 10,000 $2.7 $27,000
Option
Stock Option (Right to Buy) 30,000 $2.7 $81,000
Option
Common Stock 10,000 $2.7 $27,000
Option
Common Stock 30,000 $2.7 $81,000
Sale
Common Stock 22,715 $34.57 $785,258
Sale
Common Stock 1,003 $37.9 $38,014
Sale
Common Stock 4,062 $35.73 $145,135
Sale
Common Stock 2,220 $36.7 $81,474
Option
Stock Option (Right to Buy) 40,000 $2.72 $108,600
Option
Common Stock 10,000 $2.7 $27,000
Sale
Common Stock 10,000 $38.02 $380,200
Option
Common Stock 30,000 $2.73 $81,900
Sale
Common Stock 30,000 $40.21 $1,206,300
Sale
Common Stock 14,566 $48.79 $710,602
Sale
Common Stock 34,156 $47.08 $1,608,167
Option
Stock Option (right to buy) 20,000 $2.7 $54,000
Sale
Common Stock 20,000 $54.27 $1,085,400
Option
Common Stock 20,000 $2.7 $54,000
Option
Stock Option (Right to Buy) 60,000 $3.25 $194,940
Sale
Common Stock 30,000 $58.88 $1,766,400
Option
Common Stock 30,000 $3.42 $102,690
Sale
Common Stock 30,000 $60.23 $1,806,750
Option
Common Stock 30,000 $2.73 $81,900
Sale
Common Stock 20,000 $4.84 $96,700
Option
Common Stock 20,000 $4.84 $96,700
Option
Stock Option (Right to Buy) 20,000 $4.84 $96,700
Option
Common Stock 30,000 N/A N/A
Option
Stock Option (Right to Buy) 30,000 N/A N/A
Option
Common Stock 30,000 $3.79 $113,550
Sale
Common Stock 30,000 N/A N/A
Sale
Common Stock 30,000 N/A N/A
Option
Stock Option (Right to Buy) 30,000 N/A N/A
Option
Common Stock 30,000 N/A N/A
Sale
Common Stock 30,000 $86.16 $2,584,770
Option
Common stock 20,000 $4.84 $96,700
Sale
Common stock 20,000 $4.84 $96,700
Option
Stock Option (right to buy) 20,000 $4.84 $96,700
Sale
Common stock 30,000 $2.73 $81,900
Option
Common stock 30,000 $4.73 $141,840
Option
Stock Option (right to buy) 30,000 $4.73 $141,840
Option
Common stock 30,000 $4.73 $141,840
Option
Stock Option (right to buy) 30,000 $4.73 $141,840
Sale
Common stock 30,000 $2.73 $81,900
Option
Common stock 30,000 $2.73 $81,900
Option
Stock Option (right to buy) 30,000 $2.73 $81,900
Sale
Common stock 20,000 $101.28 $2,025,600
Sale
Common stock 20,000 $101.28 $2,025,600
Option
Common stock 20,000 $6.62 $132,400
Option
Stock Option (right to buy) 20,000 $6.62 $132,400
Sale
Common stock 30,000 $98.76 $2,962,830
Sale
Common stock 30,000 $74.45 $2,233,560
Option
Common stock 30,000 $4.68 $140,250
Option
Stock Option (right to buy) 30,000 $4.68 $140,250
Sale
Common stock 30,000 $103.6 $3,107,850
Option
Common stock 30,000 $2.73 $81,900
Option
Stock Option (right to buy) 30,000 $2.73 $81,900
Sale
Common stock 30,000 $103.6 $3,107,850
Sale
Common stock 8,587 $110.68 $950,375
Sale
Common stock 60,820 $116.33 $7,075,008
Option
Common stock 20,000 N/A N/A
Option
Stock Option (right to buy) 20,000 N/A N/A
Sale
Common stock 20,000 N/A N/A
Sale
Common stock 17,104 N/A N/A
Option
Common stock 20,000 $51.03 $1,020,600
Option
Common Stock 10,000 $51.03 $510,300
Sale
Common stock 10,000 $51.03 $510,300
Option
Stock Option (right to buy) 30,000 $51.03 $1,530,900
Option
Stock Option (right to buy) 30,000 $2.73 $81,900
Sale
Common stock 30,000 $53.18 $1,595,430
Option
Common stock 30,000 $2.73 $81,900
Sale
Common Stock 25,000 $2.7 $67,500
Option
Common Stock 25,000 $2.7 $67,500
Option
Stock Option (right to buy) 25,000 $2.7 $67,500
Option
Common Stock 25,000 $2.7 $67,500
Option
Stock Option (right to buy) 25,000 $2.7 $67,500
Sale
Common Stock 25,000 $2.7 $67,500
Option
Stock Option (right to buy) 25,000 $2.7 $67,500
Sale
Common Stock 25,000 $2.7 $67,500
Option
Common Stock 25,000 $2.7 $67,500
Sale
Common Stock 21,017 $14.44 $303,464
Sale
Common Stock 14,335 $19 $272,422
Option
Stock Option (right to buy) 14,335 $1.63 $23,366
Option
Common Stock 14,335 $1.63 $23,366
Option
Common Stock 11,459 $16.01 $183,504
Option
Stock Option (right to buy) 11,459 $16.01 $183,504
Sale
Common Stock 6,843 $16.01 $109,584
Option
Stock Option (right to buy) 8,541 $8.91 $76,066
Sale
Common Stock 1,092 $1.63 $1,780
Option
Common Stock 8,541 $8.91 $76,066
Option
Stock Option (right to buy) 20,000 $1.63 $32,600
Sale
Common Stock 20,000 $1.63 $32,600
Option
Common Stock 20,000 $1.63 $32,600
Sale
Common Stock 800 $4.07 $3,256
Sale
Common Stock 16,368 $3.87 $63,344
Option
Common Stock 2,570 $1.37 $3,521
Option
Stock Option (right to buy) 2,570 $1.37 $3,521
Option
Stock Option (right to buy) 7,500 $1.5 $11,250
Option
Common Stock 7,500 $1.5 $11,250
Option
Common Stock 8,000 $1.5 $12,000
Option
Stock Option (right to buy) 8,000 $1.5 $12,000
Option
Common Stock 8,862 $1.37 $12,141
Option
Stock Option (right to buy) 8,862 $1.37 $12,141
Sale
Common Stock 4,019 $9.08 $36,484
Sale
Common Stock 15,981 $10.2 $162,974

Fate Therapeutics key executives

Fate Therapeutics, Inc. executives and other stock owners filed with the SEC: